Industry pushes for faster generic approvals as costs rise October 07, 2016 By Christine Blank Generic drugmakers and others are pushing for faster FDA approval of generics. Will docs prescribe the new RA biosimilars? October 07, 2016 By Christine Blank While FDA recently approved two new biosimilars for rheumatoid arthritis and other inflammatory diseases, questions remain about how quickly physicians and patients will embrace the new drugs. Five specialty pharmaceutical trends to watch October 05, 2016 By Aubrey Westgate Approvals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar. Study: New cholesterol drugs cost 356 times more than generics September 29, 2016 By Tracey Walker A report from the Alliance of Community Health Plans can help get a better sense of how well drugs help patients compared to other treatment options. Medicare drug spending spike shows need for generics September 10, 2016 By Christine Blank An exclusive Associated Press report found that Medicare’s spending on certain drugs soared by 85% in two years. What the new biosimilar means for U.S. healthcare September 09, 2016 By Christine Blank Physicians and pharmacists welcomed FDA’s recent approval of etanercept-szzs (Erelzi), a biosimilar to Amgen’s top-selling Enbrel for rheumatoid arthritis, plaque psoriasis, and other inflammatory conditions. Biosimilar naming method questioned September 09, 2016 By Christine Blank FDA’s method for naming biosimilars and interchangeable biologics came under fire long before the first biosimilar, Zarxio, was approved last spring. Study: Biosimilars as safe as branded drugs August 12, 2016 By Christine Blank New study finds that biosimilar medications for arthritis and other diseases areas safe and effective as their brand-name counterparts. Global generics drug market to grow 10% annually July 06, 2016 By Christine Blank Patents expire, competition rises, and outsourcing expands. New bill aims to support generic, biosimilar drug competition July 06, 2016 By Christine Blank The CREATES Act came about because some pharmaceutical manufacturers are misusing the REMS program to prevent generic drug development.